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Background: Adrenal Cushing’s syndrome caused by ACTH-independent macronodular adrenocortical hyperplasia
(AIMAH) can be accompanied by aberrant responses to hormonal stimuli. We investigated the prevalence of
adrenocortical reactions to these stimuli in a large cohort of AIMAH patients, both in vivo and in vitro.
Methods: In vivo cortisol responses to hormonal stimuli were studied in 35 patients with ACTH-independent
bilateral adrenal enlargement and (sub-)clinical hypercortisolism. In vitro, the effects of these stimuli on cortisol
secretion and steroidogenic enzyme mRNA expression were evaluated in cultured AIMAH and other adrenocortical
cells. Arginine-vasopressin (AVP) receptor mRNA levels were determined in the adrenal tissues.
Results: Positive serum cortisol responses to stimuli were detected in 27/35 AIMAH patients tested, with multiple
responses within individual patients occurring for up to four stimuli. AVP and metoclopramide were the most prevalent
hormonal stimuli triggering positive responses in vivo. Catecholamines induced short-term cortisol production more
often in AIMAH cultures compared to other adrenal cells. Short- and long-term incubation with AVP increased cortisol
secretion in cultures of AIMAH cells. AVP also increased steroidogenic enzyme mRNA expression, among which an
aberrant induction of CYP11B1. AVP type 1a receptor was the only AVPR expressed and levels were high in the AIMAH
tissues. AVPR1A expression was related to the AVP-induced stimulation of CYP11B1.
Conclusions: Multiple hormonal signals can simultaneously induce hypercortisolism in AIMAH. AVP is the most
prevalent eutopic signal and expression of its type 1a receptor was aberrantly linked to CYP11B1 expression.
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Cushing’s syndrome (CS) can be divided into adreno-
corticotropin (ACTH)-dependent and ACTH-independent
disease [1]. The latter can in rare cases result from ACTH-
independent macronodular adrenocortical hyperplasia
(AIMAH). AIMAH is characterized by multiple bilateral* Correspondence: j.hofland@erasmusmc.nl
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reproduction in any medium, provided the ornodules consisting of hyperplastic adrenal cells that lead
to non-ACTH-dependent (over)production of cortisol.
The hypercortisolism in AIMAH patients is caused by
an exaggerated or ectopic response to stimulation by
hormonal signals. Receptors for these hormones, euto-
pically or ectopically expressed on adrenocortical cells
and activated by endogenous hormones, stimulate intra-
cellular pathways leading to (sub-)clinical CS [2]. Aber-
rant hormonal responses and the presence of hormone
receptors in AIMAH have been well documented forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ceptor [3-5], α4-, β1- and β2-adrenergic receptor (AR)
[6,7], arginine-vasopressin (AVP) type 1a and 2 recep-
tors (AVPR1A/2) [8,9], luteinizing hormone receptor
(LHR) [10,11] and serotonin (5-HT) type 4 receptor (5-
HT4R) [12,13]. Other possible aberrantly expressed re-
ceptors include the AngII type I receptor (AT1R) [14]
and glucagon receptor [15,16].
Diagnostic protocols for AIMAH include administra-
tion of the various hormones or stimuli to patients [2].
The relevance of these effects has been shown by the re-
sults of administration of antagonists to the expressed
receptors [6,10,17], confirmation of stimulatory effects
of hormones on primary AIMAH cells in vitro and/or
the detection of the hormone receptors on AIMAH
cells. Furthermore, these effects have been described in
adrenocortical adenomas and carcinomas, which can
also overexpress receptors responsive to endocrine and/
or paracrine signals [17].
Whereas the presence of aberrant receptors has been
firmly established, little is known on the cause of such
altered receptor expression and on downstream signals
coupling receptor activation to stimulation of cell
growth and steroidogenesis [18,19]. Although most pa-
tients present sporadically, some AIMAH cases occur in
families [20], suggesting a possible genetic background.
Investigations in murine models have shown that ad-
renal overexpression of GIP [21] and LH receptors [22]
can lead to AIMAH and adrenal CS. This implies that
the aberrant expression of these GPCRs may play a role
in adrenal cell hyperplasia apart from modulating corti-
sol production. Most evidence on AIMAH pathophysi-
ology in humans has been collected from case reports,
small case series and reviews; only three centers have
reported on larger groups of 16, 18 and 32 AIMAH pa-
tients, respectively [7,16,19]. Furthermore, no large
series have systematically related clinical data to corre-
sponding in vitro findings.
The current study evaluated the presence of aberrant
hormonal responses in patients with AIMAH in order to
discover novel pathways involved in the pathophysiology
of this rare disease. We performed in vivo and in vitro
stimulation tests with ACTH and multiple ligands for
hormone receptors in the largest group of AIMAH pa-
tients described so far.
Subjects and methods
Patients
We included patients that presented with ACTH-
independent bilateral adrenal enlargement with (sub-)clin-
ical CS between 1994 and 2011. Clinical CS was defined
by the presence of clinical symptoms and positive tests for
hypercortisolism: the absence of a cortisol diurnal rhythm,
increased 24h urinary free cortisol excretion, suppressedACTH levels and/or failure to suppress cortisol levels
below 50 nmol/l after 1mg dexamethasone overnight. Sub-
clinical CS was defined by one or more positive tests for
hypercortisolism in the absence of overt signs and symp-
toms of CS according to [23]. The study was approved by
the medical ethical committee of the Erasmus MC and is
in accordance with the use of residual tissues according to
the Medical Research Involving Human Subjects Act.
All patients were admitted for measurement of base-
line hormonal levels and subsequent administration of
hormonal stimuli: 250 μg synacthen (Novartis, Basel,
Switzerland) iv, 100 μg LH releasing hormone (LHRH,
Ferring, Hoofddorp, The Netherlands) iv, 200 μg thyro-
tropin releasing hormone (TRH, Ferring) iv, a 2 h up-
right posture test, 10 mg metoclopramide (Pharmachemie,
Haarlem, The Netherlands) orally, 1mg glucagon (Novo
Nordisk, Alphen aan den Rijn, The Netherlands) iv, intra-
venous salt loading (NaCl 3% at 0.1 cc/kg/min) and a
standard mixed meal (116 g carbohydrates, 27 g proteins,
14 g fat). From 2002 on, the intravenous salt loading test
was replaced by intramuscular injection of 10 IU AVP
(Ferring) [2]. ACTH levels were measured during the up-
right posture, intravenous salt loading and vasopressin
tests to exclude effects of AVP on pituitary ACTH secre-
tion. In case of clinical CS patients underwent bilateral
laparoscopic adrenalectomy and were put on lifelong
glucocorticoid and mineralocorticoid replacement.
Tissue processing
Adrenal tissue was collected following adrenalectomy
due to renal cell carcinoma (normal, n=3), AIMAH
(n=22), ACTH-dependent hyperplasia (n=11), adreno-
cortical adenoma (n=11) or carcinoma (n=4). Parts of
the tissue were stored at −80°C until RNA isolation.
Other tissue parts were minced and transferred to a tube
containing DMEM/F12 containing 5% fetal calf serum
(FCS), penicillin and streptomycin (Invitrogen, Carlsbad,
USA). Subsequently, tissues were dispersed into single
primary adrenal cell suspensions using collagenase type I
(Sigma-Aldrich, St. Louis, USA) as previously described
[24]. Adrenal cell viability was checked with trypan blue
and always exceeded 90%. 1,000,000 cells were put into
5 ml tubes for short-term incubations and, in case of
sufficient cell yield, plated in 24 well plates at 100,000
cells per well for long-term culture.
Short-term incubation
The cells were incubated in quadruplicate in a 2 ml
volume containing 5% FCS with the following secreta-
gogues: vehicle, ACTH, GIP (Sigma), metoclopramide,
hCG (Organon, Oss, The Netherlands), epinephrine, nor-
epinephrine (Centrafarm, Etten-Leur, The Netherlands),
glucagon, AVP (Monarch Pharmaceuticals, Bristol, USA),
desmopressin (Ferring), AngII (Sigma) or TSH (Genzyme,
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(FSK, Sigma) was added as a positive control. Secreta-
gogues were selected on the basis of positive in vivo re-
sponses obtained in individual AIMAH patients. After the
addition of hormones, tubes were incubated in a rocking
water bath at 37°C for 2 h. Supernatants were removed
and stored at −20°C until the measurement of cortisol.
Long-term cell culture
Cells were allowed to attach overnight and the medium
was changed to serum free DMEM/F12 the next day.
After 24 h the hormonal stimuli also used for short-term
incubation were added in quadruplicate and cells were
cultured at 37°C for 48 h. Subsequently, supernatants
were removed and stored at −20°C, whereas the attached
cells were stored at −80°C until the isolation of RNA.
Cortisol measurement and quantitative mRNA analysis
Cortisol levels were measured using a chemiluminescence-
based method (Immulite, Siemens Diagnostics, Deerfield,
USA; reference values for serum 200–800 nmol/l; for
urine <850 nmol/24 h). RNA was isolated from plated cells
and frozen adrenal tissue samples and reverse-transcribed
as previously described [25]. The assays for the measure-
ment of mRNA expression of the housekeeping gene
HPRT1, the cholesterol transporter steroid acute regulatory
protein (STAR) and steroidogenic enzymes (cytochrome
P450 side chain cleavage [CYP11A1], 3β-hydroxysteroid
dehydrogenase type 2 [HSD3B2], 17-hydroxylase/17,20-
lyase [CYP17A1], 21-hydroxylase [CYP21A2] and 11β-
hydroxylase [CYP11B1]) were as reported [26]. We used
SYBR green-based assays for measurements of AVPR1A
(F:TTTGTGATCGTGACGGCTTACA, R:GGTGATGGT
AGGGTTTTCCGA) and AVPR1B (F:CAGCAGCATCA
ACACCATCT, R:CCATGTAGATCCAGGGGTTG) and
purchased the AVPR2 assay from Applied Biosystems
(Hs00181055_m1). Positive controls for the assays for the
vasopressin receptors consisted of human adrenal gland,
kidney and pituitary gland, all obtained as residual tissues
during surgical procedures within the Erasmus MC.
Quantitative PCR was performed in a 12.5 μl mixture
containing 20 ng cDNA [26]. PCR efficiency exceeded
90% for all assays used. mRNA levels were calculated rela-
tive to that of HPRT1, expression of which was shown to
be stable under the conditions used, on the basis of the
δCt-method.
Data analysis and statistics
A full response was defined as a more than 50% increase
of cortisol following the administration of the stimulus.
Responses between 25-50% were considered as partial
[2]. Group comparisons were made with Kruskal-Wallis
followed by Dunn’s multiple comparison tests. Dif-
ferences between 2 groups were analyzed by Mann–Whitney U or Wilcoxon signed rank tests for unpaired
and paired observations, respectively. Spearman’s correl-
ation coefficient was used for analysis of association be-
tween variables. Multiple testing was adjusted for by
Bonferroni correction. All tests were calculated as two-
tailed and a P-value below 0.05 was considered to be sta-
tistically significant.
Results
In vivo studies
Thirty-five AIMAH patients underwent in vivo evaluation
of cortisol responses to eutopic and ectopic hormonal
stimuli. Patient characteristics and basal hormone levels
are summarized in Table 1 and Additional file 1: Table S1.
All cases appeared to be sporadic; however familial screen-
ing was not performed. As expected, midnight serum cor-
tisol levels, cortisol following dexamethasone overnight
and 24 hour urinary free cortisol were all higher in pa-
tients with clinical compared to subclinical CS (all p<0.01,
Table 1). Of note, in patients with subclinical CS urinary
free cortisol levels were within the normal range whereas
the dexamethasone suppression test was disturbed in the
majority of patients. ACTH levels were suppressed in 39%
of patients with subclinical CS. Adrenal diameters were
larger in clinical CS patients than in subclinical CS
(P<0.05, Table 1).
ACTH administration increased serum cortisol 5.2±0.9-
fold compared to baseline (mean±SEM, p<0.0001); posi-
tive responses were demonstrated in all but one patient. A
single ACTH stimulation test in this patient with subclin-
ical CS increased cortisol levels from 191 nM to only 211
nM. Of the additional hormonal stimuli tested, AVP gave
the highest percentage of responses: 52% of patients
displayed a >50% increase in cortisol levels. The other
prevalent responses are also shown in Table 2 and the cor-
tisol induction by these stimuli is indicated in Figure 1A.
Overall, significant induction of cortisol was found for
AVP, upright posture, metoclopramide, LHRH, glucagon
and salt loading.
Twenty-seven (77%) patients showed a minimum of
one full response to any administrated stimulus, apart
from ACTH. One, 2, or 3 positive responses were dem-
onstrated in 10, 11 and 5 patients, respectively. One pa-
tient had a positive response to 4 aberrant stimuli at
in vivo testing (Table 2). Of the 26 patients that under-
went an upright posture test and either salt loading or
stimulation with AVP, 9 patients had discordant results,
5 (19%) of whom had only a complete response of serum
cortisol to the upright posture test. Manipulation of
angiotensin II or β-adrenergic receptors was not carried
out in patients.
The cortisol responses to a standard mixed meal
were inversely associated with the morning cortisol
levels (r=−0.473, p=0.007) and correlated positively
Table 1 Characteristics of AIMAH patients evaluated
in vivo
Total 35
Male/female 9/26
Age (years) 56.1±9.8
Adrenalectomy 22 (63%)
Hypercortisolism
- SCS 13 (37%)
- CCS 22 (63%)
Diameter adrenal (mm)
- left SCS 31.7±10.1
- left CCS 46.1±16.9*
- right SCS 27.2±8.8
- right CCS 43.6±17.0*
Hypertension
- SCS 7 (54%)
- CCS 17 (77%)
Diabetes mellitus
- SCS 6 (46%)
- CCS 6 (29%)
Bone loss
- Osteopenia
• SCS 4 (31%)
• CCS 4 (18%)
- Osteoporosis
• SCS 5 (42%)
• CCS 5 (24%)
Midnight cortisol (nmol/l)
- SCS 184±80
- CCS 319±145*
Urinary free cortisol (nmol/24h)
- SCS 481±121 (0% > URL)
- CCS 1048±197* (37% > URL)
Cortisol after dexamethasone (nmol/l)
- SCS 145±131 (92% > URL)
- CCS 296±183* (95% > URL)
ACTH (pmol/l)
- SCS 1.47±0.92 (39% nd)
- CCS 0.85±0.89 (85% nd)
SCS: subclinical Cushing’s syndrome, CCS: clinical Cushing’s syndrome, URL:
upper reference limit, nd: non-detectable, data presented as mean±SD,
*P<0.05, compared to SCS. ¶ ACTH levels below the lower detection limit of
1.10 pmol/l were set at 0.55 pmol/l.
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were no significant differences in cortisol induction fol-
lowing the hormonal stimuli between patients with sub-
clinical and clinical CS.Short-term in vitro studies
Cells for short-term (2 h) primary incubations were suc-
cessfully obtained from the resected adrenal tissues in
14 out of 22 (64%) operated AIMAH patients (Table 3).
Due to limited availability of cells, cultures could not be
incubated with the complete panel of secretagogues
(Additional file 1: Table S1). Incubation with ACTH
(500 pg/ml) induced a full response in 60% of cultures.
Augmented supernatant cortisol levels were found in 1
out of 4 cultures (25%) incubated with 100 nM AVP. In
comparison, short-term metoclopramide incubation gave
a full response in 2 out of 7 (29%) primary cultures. Nor-
epinephrine, glucagon, desmopressin, hCG, angiotensin
II and TSH did not augment cortisol secretion above
50% in any of the cultures investigated.
The mean cortisol induction was significant after 50 and
500 pg/ml ACTH (2.82±0.98-fold, p=0.018 and 2.06±0.27-
fold, p=0.005), FSK (2.31±0.41-fold, p=0.005) and norepin-
ephrine (1.16±0.04-fold, p=0.016), but not for the other
stimuli (Figure 1B). Overall associations between hormo-
nal effects obtained in vivo and in vitro were not signifi-
cant for any of the stimuli investigated (Table 3). Similarly,
tissues of patients who showed a complete response for a
particular stimulus in vivo did not show higher cortisol
levels after incubation with the hormonal equivalent com-
pared to non-responders.
Short-term incubations were also performed with cells
from 19 other adrenal tissues, consisting of 1 normal ad-
renal gland, 10 ACTH-dependent hyperplasias and 8 ad-
renocortical adenomas (Table 3 and Figure 1B). In vivo
investigations were not available for these patients. In
vitro responses to all individual stimuli were not signifi-
cantly different between adrenal hyperplasia and aden-
oma samples. Full or partial cortisol responses were only
observed after incubation with ACTH, FSK, AngII, AVP,
metoclopramide and GIP. Only the mean cortisol re-
sponses to epinephrine and norepinephrine were signifi-
cantly higher in AIMAH cultures than in the non-
AIMAH cultures (P<0.05, Figure 1B).
Long-term in vitro studies
Seven AIMAH tissues yielded sufficient cells to perform
concurrent 48 h incubations with hormonal stimuli. The
cortisol responses are shown in Table 4 and Additional file
1: Table S1. Again AVP (86%) and metoclopramide (50%)
were the non-ACTH stimuli that most often led to >50%
increases in cortisol levels. The mean induction of cortisol
was only significant following the addition of ACTH
(4.55±1.51-fold, p=0.016) and 100 nM AVP (2.21±0.32-fold,
p=0.016), see Figure 1C; the sample sizes for the other
groups were small. Again, there was a poor overall correl-
ation between effects obtained in vivo and in vitro (Table 4).
Cortisol levels did not increase after incubation of cells
from the in vivo responders with the corresponding stimuli.
Table 2 In vivo response to hormonal stimuli in patients with AIMAH
Stimulus n tested Partial response (25-50%) n (%) Full response ≥50%) n (%)
ACTH1-24 29 - 28 (97%)
Posture 26 4 (15%) 13 (50%)
Salt loading 6 1 (17%) 1 (17%)
AVP 21 6 (29%) 12 (52%)
Metoclopramide 29 3 (10%) 7 (24%)
LHRH 30 5 (17%) 5 (17%)
TRH 29 2 (7 %) 3 (10%)
Glucagon 26 4 (15%) 4 (15%)
Mixed meal 32 2 (6%) 6 (18%)
Number of aberrant responses n n
0 20 8
1 8 10
2 4 11
3 3 5
4 0 1
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mRNA levels of STAR and the steroidogenic enzymes in-
volved in cortisol synthesis (Figure 2). ACTH and AVP
at 100 nM stimulated the expression of the cholesterol
transporter and all steroidogenic enzymes studied in the
AIMAH cultures. Although stimulatory effects were also
found for the other secretagogues, these effects did not
reach statistical significance, likely due to the small sam-
ple size (n≤4).
For this reason, we focused further on AVP and concur-
rently measured AVP effects in long-term adrenal cell cul-
tures of non-AIMAH origin (i.e. 3 normal adrenals, 1
ACTH-dependent hyperplasia, 3 adenomas and 4 carcin-
omas). AVP at 100 nM significantly increased cortisol
secretion in the 7 primary adrenal cell cultures with detect-
able supernatant cortisol levels (2.54±0.69-fold, p=0.016).
AVP induced a >50% increase in cortisol levels in 71% of
non-AIMAH adrenal cultures. The effects on steroido-
genic enzyme mRNA expression after the addition of AVP
were comparable between cultures from AIMAH cells
and other adrenocortical tissues, with the exception of
CYP11B1 (Figure 2). 48 h culture in the presence of AVP
stimulated CYP11B1 expression 6.34±1.57-fold in AIMAH
cells, compared to a 2.66±0.97-fold induction in cells of
non-AIMAH adrenal origin (p=0.033). AVP-stimulated
cortisol and CYP11B1 levels were equal among the differ-
ent groups of non-AIMAH tissues.
AVP receptor expression
Expression of mRNA of vasopressin receptors (AVPR1A,
AVPR2, AVPR1B) was studied in a panel of adrenocortical
tissues, consisting of AIMAH, normal adrenals, ACTH-dependent hyperplasias, adenomas and carcinomas. The V3
(AVPR1B) was not detectable in any of the adrenocortical
tissues studied, whereas V2 (AVPR2) mRNA was detectable
in 10 out of the 29 samples, distributed among all groups,
but at very low levels (Ct values>38). The ubiquitously
expressed AVPR1A mRNA was found to be highest in the
AIMAH samples. The expression levels in AIMAH were
significantly increased compared to those in adrenocortical
carcinomas (p=0.037, Figure 3A). AIMAH AVPR1A levels
were not associated with clinical characteristics or the
in vivo or in vitro cortisol induction following upright pos-
ture or AVP administration (p>0.05). On the other hand,
AVPR1A levels in all tissues were significantly associated
with the in vitro induction of CYP11B1 by 100 nM AVP
(r=0.76, p=0.006, Figure 3B).
Discussion
AIMAH is a rare disease associated with the presence of
aberrantly expressed eutopic and ectopic receptors on ad-
renocortical cells [2]. In the current study, ACTH still
formed the most potent stimulus for steroidogenesis in
AIMAH. ACTH stimulated cortisol production in vivo
and in vitro in almost all patients. One patient showed
only 10% increase in cortisol levels following ACTH.
Unfortunately, repetitive testing was not available and in-
correct administration or sample handling cannot be ex-
cluded in this case. The induction of cortisol by ACTH
was comparable in primary cultures of AIMAH and non-
AIMAH origin. We have previously demonstrated that
MC2R levels, which are controlled by ACTH signaling
through cAMP [27,28], are equal in AIMAH and other ad-
renal tissues [29]. Although plasma ACTH levels are low
Figure 1 (See legend on next page.)
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Figure 1 In vivo and in vitro induction of cortisol production following administration of hormonal stimuli. (A) Patients were tested for
the presence of aberrant expression of eutopic or ectopic hormone receptors by the administration of hormonal stimuli in various tests indicated
on the X-axis. Line represents mean. *p<0.05, **p<0.01, ***p<0.001 compared to basal level (Wilcoxon signed rank test). (B) Primary cell cultures
from AIMAH tissues (white bars) or from normal adrenals, ACTH-dependent adrenocortical hyperplasia or adenomas (other, black bars) were
incubated for 2 h in the presence of specific hormone receptor agonists indicated on the X-axis. Concentrations used have been summarized in
Table 3. Data are represented as mean+SEM. *p<0.05, **p<0.01, ***p<0.001 compared to vehicle control (Wilcoxon signed rank) or between
pathological entities (Mann–Whitney U test). (C) Cortisol induction in media of AIMAH or other adrenal cells after 48 h incubation with specific
hormone receptor agonists. Concentrations used are summarized in Table 4. Data are represented as mean+SEM. *p<0.05 compared to vehicle
control (Wilcoxon signed rank). Numbers of patients are shown in Tables 2, 3 and 4.
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pathways in AIMAH cells could stimulate cAMP forma-
tion and thereby ensure MC2R expression.
The most prevalent exaggerated responses to hormonal
stimulation in AIMAH patients were to AVP and upright
posture, confirming previous findings [16]. Several studies
have now demonstrated the presence of the eutopically
expressed V1 receptor in AIMAH tissues [9,30]. The
(near) undetectable levels of V2 and V3 receptors com-
bined with the absence of effects of desmopressin, a select-
ive V2 agonist, plead against significant roles of these latter
receptors in AIMAH. Although no overall significant dif-
ferences in AVPR1A mRNA levels between AIMAH and
other adrenal cells were detected [9,30], individual patients
could still overexpress the V1 receptor [31-33]. AVP
induced cortisol and mRNA expression of StAR and four
steroidogenic enzymes uniformly in AIMAH and non-
AIMAH cells, suggesting that AVP has a physiological
effect on adrenocortical steroidogenesis. However, theTable 3 Two hour in vitro cortisol responses to hormonal stim
AIMAH
Dose n Partial response
(%)
Full response
(%)
ACTH1-24 50 pg/ml 7 2 (29%) 4 (57%)
ACTH1-24 500 pg/
ml
10 3 (30%) 6 (60%)
FSK 1 μM 8 0 7 (88%)
AngII 10 nM 2 0 0
AVP 10 nM 6 2 (33%) 1 (17%)
AVP 100 nM 4 1 (25%) 1 (25%)
Desmopressin 10 nM 5 0 0
Metoclopramide 1 μM 7 0 2 (29%)
Epinephrine 1 μM 7 1 (14%) 1 (14%)
Norepinephrine 1 μM 7 1 (14%) 0
hCG 100 IU/ml 10 3 (30%) 0
TSH 10 nM 4 0 0
Glucagon 1 μM 4 0 0
GIP 100 nM 6 1 (17%) 1 (17%)
¶ standard mixed meal, # upright posture test, † AVP im, n.a.: not applicable.selective stimulation of CYP11B1, a key enzyme in cortisol
synthesis, in AIMAH by AVP indicates a novel molecular
mechanism underlying the coupling between the V1 re-
ceptor and steroidogenesis in AIMAH. This suggestion is
supported by the association between AVPR1A levels and
the AVP-induced mRNA expression of CYP11B1. This
correlation between receptor levels and cortisol stimula-
tion is not present for MC2R and ACTH [29]. More effi-
cient coupling of the V1 receptor to 11β-hydroxylase
could form a cause of AIMAH that is characterized by
normal GPCR levels. These findings in AIMAH might
open up new opportunities for medical treatment with se-
lective V1 receptor antagonists [34]. Adrenocortical carcin-
omas seem to have an impaired response to AVP, possibly
due to decreased expression of the type V1 receptor.
The upright posture test was positive in half of the pa-
tients studied in vivo. Of the 13 patients with a positive
response to upright posture, 8 reacted also positively to
AVP administration. The other 5 patients could haveuli in primary adrenal cell cultures
Non-AIMAH
Correlation with in vivo
test
n Partial response
(%)
Full response
(%)
0.30 5 1 (20%) 4 (80%)
0.07 18 1 (6%) 16 (89%)
0.29 9 0 7 (78%)
n.a. # 2 1 (50%) 1 (50%)
−0.72†; -0.50# 4 1 (25%) 0
−1.00†; -0.80# 3 1 (33%) 0
−0.80 3 0 0
0.71 14 3 (21%) 0
−0.50# 5 0 0
−0.15# 5 0 0
0.60 4 0 0
−0.32 1 0 0
0.50 1 0 0
0.49¶ 4 1 (25%) 0
Table 4 Forty-eight hour in vitro cortisol responses to hormonal stimuli in AIMAH cells
Dose n Partial response n (%) Full response n (%) Correlation with in vivo test Correlation with t=2 h
ACTH1-24 10 ng/ml 7 0 6 (86%) −0.39 0.20
AngII 100 nM 4 0 4 (100%) 1.00**# n.a.
AVP 10 nM 3 0 2 (67%) 0.50†; n.a.# n.a.
AVP 100 nM 7 1 (14%) 6 (86%) −0.18†; -0.086# −0.50
Desmopressin 10 nM 5 0 0 −0.67 1.00**
Metoclopramide 1 μM 4 0 2 (50%) 0.60 1.00**
Norepinephrine 1 μM 4 0 0 −0.50# −0.50#
hCG 100 IU/ml 4 0 0 −0.60 −0.50
TSH 10 nM 2 0 1 (50%) n.a. n.a.
Glucagon 1 μM 4 0 0 −0.20 n.a.
GIP 100 nM 2 0 0 −1.00¶ n.a.
**p<0.01, ¶ standard mixed meal, # upright posture test, † AVP im, n.a. not applicable.
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[2]. Interestingly, in the short-term experiments we
found a difference in responsiveness to catecholamines
between AIMAH and non-AIMAH cells. In contrast to
the observation with AVP, this would suggest the presenceFigure 2 Induction of STAR and steroidogenic enzyme mRNAs followi
tissues (white bars) or from normal adrenals, ACTH-dependent adrenocortic
incubated for 48 hours in the presence of hormones depicted on X-axis. C
STAR, CYP11A1, HSD3B2, CYP17A1, CYP21A2 and CYP11B1 were studied by q
represented as mean+SEM. *p<0.05, **p<0.01, compared to basal level (Wi
U test).of ectopic adrenergic receptors. Previous studies revealed
that this could be related to adrenocortical expression of
β1-, β2- or α4-adrenergic receptors [6,7].
The type 4 serotonin receptor (5HT4R) is expressed in
the adrenal gland and its activation can affect cortisolng addition of hormonal stimuli. Primary cell cultures from AIMAH
al hyperplasia, adenomas or carcinomas (other, black bars) were
oncentrations used are summarized in Table 4. The mRNA levels of
uantitative RT-PCR and calculated relative to HPRT1 expression. Data are
lcoxon signed rank) or between pathological entities (Mann–Whitney
Figure 3 AVP receptor expression in adrenal tissues. (A) AVP type 1a receptor (V1, AVPR1A) mRNA expression in human adrenocortical tissues
(Nl: normal, Hyp: ACTH-dependent hyperplasia, ADA: adrenocortical adenoma, ACC: adrenocortical carcinoma), measured by qRT-PCR. R.U.: relative
units, compared to HPRT1 expression. *p<0.05, Kruskal-Wallis test. V2 and V3 receptor expression levels were extremely low or undetectable.
(B) Significant correlation between AVPR1A expression levels and the induction of CYP11B1 by 100 nM AVP after 48 hours in cultures of primary
cells of adrenal tissues. Corresponding icons for individual tissue groups are depicted in Figure A and B.
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http://www.ojrd.com/content/8/1/142production [35,36]. In the present study, 34% of patients
had a >25% stimulation of serum cortisol levels following
metoclopramide, an agonist of 5-HT4R, which was less
than the 56% observed in the previous study [16]. In vitro,
this response was also found in AIMAH samples as well
as in controls. Moreover, there was no significant differ-
ence in response between AIMAH and non-AIMAH cells
in vitro, making it questionable whether the response to 5-
HT in AIMAH patients is truly aberrant.
Other hormonal stimuli can lead to a stimulation of
serum cortisol in a minority of AIMAH cases. For LHRH,
TRH, glucagon and GIP we have found that this is the case
in 10-22% of patients. Adrenal LHR or GIPR expression
was previously confirmed in 6 patients [5,11,33,37,38]. Theassociation between cortisol induction following ACTH
and after the standard mixed meal could be caused by
food-induced stimulation of ACTH [39,40]. Unfortu-
nately, we have no data on postprandial ACTH levels in
these patients. The inverse correlation between morn-
ing cortisol and cortisol induction by a mixed meal re-
flects higher cortisol increments in patients with low
basal cortisol levels. The cause of this finding is un-
known, but might reflect higher adrenal sensitivity to
GIP at lower cortisol levels. In vitro, we found no major
effects of the other hormonal stimuli on cortisol pro-
duction besides in individual cultures.
The clinical description of AIMAH cases has often
been coupled with in vitro investigations on patient
Hofland et al. Orphanet Journal of Rare Diseases 2013, 8:142 Page 10 of 12
http://www.ojrd.com/content/8/1/142tissue samples. Several AIMAH patients with discrepan-
cies between clinical and experimental hormonal re-
sponses have been described [41,42], which is in
contrast to the majority of AIMAH studies in which
identical in vitro and in vivo hormonal effects are
obtained (reviewed in [2]). We have evaluated in vitro
responses in 17 primary cultures of AIMAH tissues and
detected a poor overall correlation between clinical and
experimental responses to individual stimuli. Possible
causes include publication bias of those patients in
whom effects could be replicated in vitro, hormonal ef-
fects through the pituitary, the concentrations of stimuli
used in vitro or the experimental set-up. Since ACTH
levels were currently only measured in the in vivo re-
sponse tests relating to AVP, effects of the other hormo-
nal stimuli through pituitary secretion of ACTH cannot
be excluded and might also cause dissociation between
clinical and experimental effects. With respect to the lat-
ter cause, we also found clear differences and an overall
lack of association between short-term and long-term ef-
fects of the stimuli on cortisol concentrations. These
conclusions should however be drawn with caution due
to the small sample sizes of cultures in some of the
short- and long-term experiments. Besides the rarity of
the disease, the low percentage of patients being oper-
ated because of clinical disease and the multitude of test-
able hormonal stimuli hamper large in vitro studies with
all possible secretagogues in AIMAH patients. Also in
this study limited availability of cells did not allow for
systematic in vitro evaluation of all possible stimuli.
Responses to the aberrant hormonal stimuli were not
associated with in vivo hormonal activity since patients
with clinical and subclinical CS showed comparable re-
sults to stimuli. It should be emphasized that the defin-
ition of subclinical CS is controversial as some clinical
symptoms of CS can be recognized in patients with sub-
tle cortisol overproduction. In addition, no cut-off values
of diagnostic tests have been established that define sub-
clinical hypercortisolism. The findings on in vivo respon-
siveness to hormonal stimuli are a confirmation of an
earlier study [16], in which it was postulated that clinical
and subclinical CS represent a continuum of disease rather
than two separate entities. This hypothesis is supported by
the smaller adrenal sizes detected in subclinical CS patients;
these patients could progress into clinical CS when adrenal
size and coupled steroidogenic capacity increase.
Exaggerated responses to hormonal stimuli have been
reported for multiple cases and case series in adrenal
hyperplasia and adenomas, although the responses in
healthy individuals have not been investigated for all hor-
mones. It is therefore uncertain to what extent in vivo
responses are the results of aberrant expression patterns
of hormone receptors. Previous [36,43] and current
in vitro data obtained in the non-AIMAH tissues suggestsignificant effects of AVP and possibly 5-HT. In our ana-
lysis we found no differences in responsiveness to hormo-
nal stimuli among ACTH-dependent hyperplasia, adrenal
adenoma and carcinoma samples, although numbers were
small. Systematic in vivo comparisons for responses be-
tween healthy individuals and AIMAH patients might im-
prove the definition of an aberrant response. The
arbitrarily used criterion of >50% elevation in serum corti-
sol may also be modified if effects in healthy individuals
would be identified.Conclusions
Multiple hormonal responses frequently occur in AIMAH
patients, with AVP and 5-HT most commonly triggering
aberrant eutopic responses. AVP induces steroidogenic en-
zyme expression in both AIMAH and non-AIMAH adre-
nocortical tissues. However, in AIMAH there appears to
be an aberrant coupling of normal levels of AVPR1A ex-
pression to the induction of CYP11B1 expression that may
be involved in the pathogenesis of AVP-mediated cortisol
overproduction. This may provide an opportunity for
medical treatment, targeting the AVP type 1a receptor in a
subset of AIMAH patients. Catecholamines appear to rep-
resent the most prevalent in vitro ectopic response in
AIMAH patients.Additional file
Additional file 1: Results of clinical and experimental hormonal
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